Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Study to Select a Once Daily Dose of GSK1349572 Administered With Either Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects

NCT00951015 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT00951015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00951015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Study to Select a Once Daily Dose of GSK1349572 Administered With Either Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Lead sponsor
ViiV Healthcare
Phase
Phase 2
Overall status
Completed
Start date
July 30, 2009
Completion date
December 22, 2016
Enrollment
208 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

infection, human immunodeficiency virus